Crisis tests a business's culture. It also is a good time to create or strengthen a culture.
In order to navigate the new landscape COVID-19 has brought along with it and connect with consumers who may be feeling confused and stressed out, lesser-known health insurers will need to introduce themselves to this new audience.
Sharing technologies like blockchain could help healthcare institutions establish a consistent, accurate, and trustworthy approach to data collection and dissemination.
The growth of digital twin technology — paired with the transition towards personalized medicine — has left many healthcare industry professionals evaluating the potential of a “patient twin.”
Medical debt can send people into “a spiral of economic disadvantage,” including a lack of stability and security in personal life, housing and work.
The ‘payvider’ model is best suited for health systems that want to double down on value-based care.
Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for Pharmacoeconomics and Outcomes Research (ISPOR) webinar.
A reduction in emergency room visits is just one of the ways teledermatology has improved patient outcomes and reduced costs, according to Elizabeth K. Jones, M.D., an associate dermatology professor at Thomas Jefferson University Hospital in Philadelphia.
COVID-19 sped up healthcare’s digital transformation. The 20-minute telehealth visit can mean less unpaid time off from work and the difference between seeking care and putting food on the table. Care-at-home programs can reduce the risks associated with hospitalization, such as hospital-acquired infections.
Five years ago, health care providers didn’t see mobile as a priority or a necessary tool in improving the patient experience. The pandemic changed that.
Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.
As payer and provider organizations look to improve health outcomes around the far-reaching impacts of the pandemic, they must consider the unique needs of some of our most vulnerable populations, such as new and expecting mothers and their infants.
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
Enterprise imaging platforms would enable organizations to consistently and optimally capture, index, manage, store, distribute, view, exchange and analyze all clinical imaging and multimedia content, enhancing patients’ electronic health records.
Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not impact formulary coverage.
The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate beta cells in patients with early type 1 diabetes.
Predictions for 2025 by Tracy Baroni Allmon, J.D., vice president of Market Access and Policy at Magnolia Market Access.
Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival (PFS). Cemiplimab’s outcomes align well with other PD-1/PD-L1 inhibitors, influencing clinical decisions for its use as a first-line treatment.
Due to one of the most challenging global crises in living memory and one that presented an acute challenge for the medical community, healthcare providers find themselves operating within an uncertain landscape. They are still managing the fallout of COVID-19 while also planning for the future.
Pharmacogenomics looks at how genetic influences affect an individual’s response to therapeutic medications.
The delivery of care model needs to scale across the community settings while servicing the unique needs of each patient.
Recent study finds that Medicaid coverage for some of the first gene and cell therapies was at times delayed and not consistent with federal requirements.
Identifying the right payer before a healthcare service is provided and billing on time, reduces costs, prevents bad debt and maximizes reimbursements and revenue.
Organizations setting up hospital-at-home programs need to be aware of the associated risks and mitigation best practices.
How AI-powered technology and its data-driven insights improve payer operations and reimburse providers faster.
CMS and state officials are using payment incentives, data collection and program requirements to start edging the lofty ideals of health equity toward reality.
Engaging with payers in collaborative arrangements is critical for achieving quality outcomes at lower cost, while ensuring financial health for providers during good times and bad.
Plan sponsors should begin evaluation of PBM performance at least a year before the contract expires, say lawyers with expertise in PBM contracting.